NORMAL ACTIVATION OF THE SUPPLEMENTARY MOTOR AREA IN PATIENTS WITH PARKINSONS-DISEASE UNDERGOING LONG-TERM TREATMENT WITH LEVODOPA

被引:137
|
作者
RASCOL, O
SABATINI, U
CHOLLET, F
FABRE, N
SENARD, JM
MONTASTRUC, JL
CELSIS, P
MARCVERGNES, JP
RASCOL, A
机构
[1] UNIV HOSP CTR,DEPT NEUROL,TOULOUSE,FRANCE
[2] UNIV ROMA LA SAPIENZA,DEPT NEUROL SCI,ROME,ITALY
[3] FAC MED TOULOUSE,NATL INST HLTH & MED RES,INSERM,U230,MED & CLIN PHARMACOL LAB,TOULOUSE,FRANCE
来源
关键词
D O I
10.1136/jnnp.57.5.567
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Regional cerebral blood flow (rCBF) changes in cortical motor areas were measured during a movement of the dominant right hand in 15 patients with Parkinson's disease deprived of their usual levodopa treatment, in 11 patients with Parkinson's disease undergoing long-term treatment with levodopa, and in 15 normal volunteers. The supplementary motor areas were significantly activated in the normal subjects and in the patients receiving levodopa but not in the patients deprived of levodopa. The contralateral primary sensory motor area was significantly activated in all three groups. The ipsilateral primary sensory motor cortex was not activated in the normal subjects and the non-treated patients but was in the patients treated with levodopa. It is concluded that the supplementary motor area hypoactivation which is observed in akinetic nontreated patients with Parkinson's disease is not present in patients undergoing long-term treatment with levodopa. This result suggests that (a) levodopa improves the functional activity of supplementary motor areas in Parkinson's disease and (b) there is no pharmacological tolerance to this effect. The ipsilateral primary motor cortex activation observed in the patients treated with levodopa could be related to levodopa-induced induced abnormal involuntary movements.
引用
收藏
页码:567 / 571
页数:5
相关论文
共 50 条
  • [21] SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSONS-DISEASE
    MARSDEN, CD
    PARKES, JD
    LANCET, 1977, 1 (8007): : 345 - 349
  • [22] CEREBRAL ATROPHY AND LONG-TERM RESPONSE TO LEVODOPA IN PARKINSONS-DISEASE
    SCHNEIDER, E
    FISCHER, PA
    JACOBI, P
    BECKER, H
    BEYER, M
    JOURNAL OF NEUROLOGY, 1979, 222 (01) : 37 - 43
  • [23] LONG-TERM TREATMENT OF PARKINSONS-DISEASE WITH BROMOCRIPTINE
    RASCOL, A
    GUIRAUD, B
    MONTASTRUC, JL
    DAVID, J
    CLANET, M
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1979, 42 (02): : 143 - 150
  • [24] SIDE-EFFECTS INDUCED BY LONG-TERM ADMINISTRATION OF LEVODOPA IN PATIENTS WITH PARKINSONS-DISEASE
    KEREN, R
    MELAMED, E
    LAVY, S
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1979, 15 (03): : 297 - 297
  • [25] PANIC ATTACKS IN PARKINSONS-DISEASE - A LONG-TERM COMPLICATION OF LEVODOPA THERAPY
    VAZQUEZ, A
    JIMENEZJIMENEZ, FJ
    GARCIARUIZ, P
    GARCIAURRA, D
    ACTA NEUROLOGICA SCANDINAVICA, 1993, 87 (01): : 14 - 18
  • [26] LONG-TERM THERAPY OF PARKINSONS-DISEASE WITH AMANTADINE, ALONE AND COMBINED WITH LEVODOPA
    ZELDOWICZ, LR
    HUBERMAN, J
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1973, 109 (07) : 588 - 593
  • [27] SELEGILINE IN THE TREATMENT OF PARKINSONS-DISEASE - LONG-TERM EXPERIENCE
    YAHR, MD
    ELIZAN, TS
    MOROS, D
    ACTA NEUROLOGICA SCANDINAVICA, 1989, 80 : 157 - 161
  • [28] LISURIDE IN PARKINSONS-DISEASE - NAIVE AND LONG-TERM TREATMENT
    MARTIGNONI, E
    SUCHY, I
    PACCHETTI, C
    SINFORIANI, E
    SANDRINI, G
    NAPPI, G
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 1986, 39 (05): : 696 - 708
  • [29] LONG-TERM EFFICACY OF CONTROLLED-RELEASE CARBIDOPA LEVODOPA IN PATIENTS WITH ADVANCED PARKINSONS-DISEASE
    MARK, MH
    SAGE, JI
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 1989, 19 (06): : 415 - 421
  • [30] CHOLINERGIC AND DOPAMINERGIC MECHANISMS IN PARKINSONS-DISEASE AFTER LONG-TERM LEVODOPA ADMINISTRATION
    YAHR, MD
    CLOUGH, CG
    BERGMANN, KJ
    LANCET, 1982, 2 (8300): : 709 - 710